On May 17, 2021, Shenzhen YHLO Biotech Co., Ltd. was listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange. Stock abbreviation: YHLO, stock code: 688575. The number of A shares publicly issued this time is 41 million shares, the issue price is 14.80 yuan per share, and the opening price is 65 yuan per share.

Shenzhen YHLO Biotech Co., Ltd. was established in 2008. The main business is the research and development, production and sales of in vitro diagnostic equipment and supporting reagents based on chemiluminescence immunoassay, and the agency sales of some non-self-produced medical device products. The company's independent research and development of in vitro diagnostic products are widely used in autoimmune diseases, reproductive health, diabetes, respiratory pathogens and other fields, and has grown into one of the leading brands of domestic chemiluminescence.

In the first quarter of 2021, YHLO Biotech have an operating income of 236 million yuan and a net profit of 37.66 million yuan.

Revenues in 2020, 2019, and 2018 were 999 million yuan, 877 million yuan, and 729 million yuan, respectively; the corresponding net profits for the same period were 210 million yuan, 107 million yuan, and 38.033 million yuan.